Developing an objective marker to optimize patient selection and predict survival benefit in early‐phase cancer trials

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|2|262-270

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.2, 2014-01, pp. : 262-270

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Separation Tests for Early-Phase Complementary and Alternative Medicine Comparative Trials

By Aickin Mikel  

Evidence-Based Integrative Medicine, Vol. 1, Iss. 4, 2004-01 ,pp. : 225-231

Adis International

Access to resources Recommend Favorite

Patient Expectations of Benefit from Phase I Clinical Trials: Linguistic Considerations in Diagnosing a Therapeutic Misconception

By Weinfurt K.P.  

Theoretical Medicine, Vol. 24, Iss. 4, 2003-01 ,pp. : 329-344

Springer Publishing Company

Access to resources Recommend Favorite

Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials

By  

Oncology Research and Treatment, Vol. 36, Iss. 6, 2013-05 ,pp. : 357-362

Karger

Access to resources Recommend Favorite

Clinical Benefit of New Targeted Agents in Phase I Trials in Patients with Advanced Colorectal Cancer

By  

Oncology, Vol. 76, Iss. 3, 2009-01 ,pp. : 151-156

Karger

Access to resources Recommend Favorite

Antithrombotics and Cancer: Evidence for Survival Benefit

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 33, Iss. 1, 2003-09 ,pp. : 67-68

Karger

Access to resources Recommend Favorite